Multiple sclerosis trials in Hungary

In Hungary 9 Also abroad 506

9 of 9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Budapest III, Tatabánya
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Budapest III, Budapest IV, Tatabánya
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Győr, Kaposvár
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
No phaseEnrolling by invitation
Objective Longitudinal Monitoring of Postural Stability and Gait During Neurorehabilitation: Clinical Application of Instrumented Posturography and Three-Dimensional Motion Analysis
Where
Kaposvár
Age
18 years to 80 years
People
151
Run by
Somogy Megyei Kaposi Mór Teaching Hospital
See details and how to joinNCT07411664
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Budapest, Kistarcsa, Pécs, Tatabánya
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Budapest III, Budapest IV, Budapest XIV, Kaposvár, Pécs
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
Phase 2Taking people
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Where
Budapest, Budapest III, Budapest IV, Budapest XIV, Debrecen, Kaposvár, Pécs
Age
18 years to 60 years
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Budapest, Budapest III, Budapest IV, Kistarcsa, Pécs, Tatabánya
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
No phaseTaking people
Functional and Quality of Life Effects of the Mollii Neuromodulatory Suit in Patients With Stroke and Multiple Sclerosis
Where
Kaposvár
Age
18 years to 99 years
People
40
Run by
Somogy Megyei Kaposi Mór Teaching Hospital
See details and how to joinNCT07333222